FDA Grants Priority Review to Novel Iobenguane I-131 Agent for Rare Neuroendocrine Tumors

December 29, 2017 – The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma (PPGL), according to a statement from Progenics Pharmaceuticals, the company developing the novel iodine-131 metaiodobenzylguanidine (MIBG). The new drug application (NDA) for iobenguane I-131 was based on findings from a phase … (leggi tutto)